InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01CA281727     (THOMPSON, TIMOTHY CHARLES)Sep 19, 2023 - Aug 31, 2028
    Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer
    Role: Principal Investigator

    R21CA255581     (HANASH, SAMIR M;THOMPSON, TIMOTHY CHARLES)Dec 8, 2020 - Nov 30, 2023
    Prostate cancer-associated SPOP mutations modulate innate immune response and immune checkpoint therapy
    Role: Principal Investigator

    R21CA223527     (THOMPSON, TIMOTHY CHARLES)Jan 1, 2018 - Dec 31, 2020
    Lipidomics-based biomarkers for risk of progression in early prostate cancer
    Role: Principal Investigator

    P50CA140388     (LOGOTHETIS, CHRISTOPHER J.)Sep 2, 2009 - Aug 31, 2023
    MD Anderson Cancer Center Prostate Cancer SPORE
    Role: Co-Principal Investigator

    R01CA068814     (THOMPSON, TIMOTHY CHARLES)Aug 1, 1995 - Feb 28, 2012
    Mechanisms of Metastasis in Experimental Prostate Cancer
    Role: Principal Investigator

    P50CA058204     (ITTMANN, MICHAEL M.)Sep 30, 1992 - May 31, 2010
    SPORE in Prostate Cancer
    Role: Co-Principal Investigator

    R01DK043523     (THOMPSON, TIMOTHY C)Sep 15, 1991 - Aug 31, 1994
    Role: Principal Investigator

    R01CA050588     (THOMPSON, TIMOTHY CHARLES)Aug 1, 1989 - May 31, 2012
    Mechanisms of Progression in Oncogene-Incuded Prostate Cancer
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Geng C, Zhang MC, Manyam GC, Vykoukal JV, Fahrmann JF, Peng S, Wu C, Park S, Kondraganti S, Wang D, Robinson BD, Loda M, Barbieri CE, Yap TA, Corn PG, Hanash S, Broom BM, Pili? PG, Thompson TC. SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression. Clin Cancer Res. 2023 11 01; 29(21):4464-4478. PMID: 37581614.
      Citations:    Fields:    Translation:Humans
    2. Linares JF, Cid-Diaz T, Duran A, Osrodek M, Reina-Campos M, Kuo HH, Elemento O, Martin ML, Cordes T, Thompson TC, Metallo CM, Moscat J, Diaz-Meco MT, Martinez-Ordo?ez A. The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62. Cell Rep. 2022 05 10; 39(6):110792. PMID: 35545049; PMCID: PMC9136538.
      Citations:    Fields:    Translation:Cells
    3. Tang Z, Geng C, Manyam GC, Yang G, Park S, Wang D, Peng S, Wu C, Peng G, Yap TA, Corn PG, Broom BM, Thompson TC, Pili? PG. ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer. Clin Cancer Res. 2021 09 01; 27(17):4898-4909. PMID: 34168048; PMCID: PMC8456453.
      Citations: 10     Fields:    Translation:AnimalsCells
    4. Wu C, Peng S, Geng C, Park S, Manyam GC, Lu Y, Yang G, Tang Z, Kondraganti S, Wang D, Hudgens CW, Ledesma DA, Marques-Piubelli ML, Torres-Cabala CA, Curry JL, Troncoso P, Corn PG, Broom BM, Thompson TC, Pili? PG. PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer. Mol Cancer Ther. 2021 09; 20(9):1680-1691. PMID: 34158347; PMCID: PMC8456452.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    5. Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BF. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol. 2021 06; 18(6):337-358. PMID: 33824525.
      Citations: 3     Fields:    Translation:Humans
    6. Han Y, Zhang M, Xu J, Li J, Xu Y, Thompson TC, Logothetis CJ, Sun D, Gu J. Genome-wide DNA methylation profiling of leukocytes identifies CpG methylation signatures of aggressive prostate cancer. Am J Cancer Res. 2021; 11(3):968-978. PMID: 33791167; PMCID: PMC7994169.
      Citations: 1     
    7. Gregg JR, Thompson TC. Considering the potential for gene-based therapy in prostate cancer. Nat Rev Urol. 2021 03; 18(3):170-184. PMID: 33637962.
      Citations: 3     Fields:    Translation:Humans
    8. Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu SM, Navone N, Thompson TC, Pisters L, Troncoso P, Davis JW, Chapin BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol. 2021 02; 79(2):298-306. PMID: 33279304.
      Citations: 4     Fields:    Translation:Humans
    9. Vykoukal J, Fahrmann JF, Gregg JR, Tang Z, Basourakos S, Irajizad E, Park S, Yang G, Creighton CJ, Fleury A, Mayo J, Paulucci-Holthauzen A, Dennison JB, Murage E, Peterson CB, Davis JW, Kim J, Hanash S, Thompson TC. Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nat Commun. 2020 08 27; 11(1):4279. PMID: 32855410; PMCID: PMC7453025.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    10. Deng Y, Xie K, Logothetis CJ, Thompson TC, Kim J, Huang M, Chang DW, Gu J, Wu X, Ye Y. Genetic variants in epithelial-mesenchymal transition genes as predictors of clinical outcomes in localized prostate cancer. Carcinogenesis. 2020 08 12; 41(8):1057-1064. PMID: 32215555; PMCID: PMC7422619.
      Citations:    Fields:    Translation:Humans
    11. Yanagisawa N, Satoh T, Tabata KI, Tsumura H, Nasu Y, Watanabe M, Thompson TC, Okayasu I, Murakumo Y, Baba S, Iwamura M. Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer. Asian J Urol. 2021 Jul; 8(3):280-288. PMID: 34401335; PMCID: PMC8356062.
    12. Vykoukal JV, Fahrmann JF, Thompson TC. Caveolin and lipid domains-close companions in managing cellular pathways. Cancer Metastasis Rev. 2020 06; 39(2):341-342. PMID: 32417992.
      Citations: 1     Fields:    Translation:HumansCells
    13. Xu J, Chang WS, Tsai CW, Bau DT, Davis JW, Thompson TC, Logothetis CJ, Gu J. Mitochondrial DNA copy number in peripheral blood leukocytes is associated with biochemical recurrence in prostate cancer patients in African Americans. Carcinogenesis. 2020 05 14; 41(3):267-273. PMID: 31408512; PMCID: PMC7456341.
      Citations: 4     Fields:    Translation:HumansCells
    14. Msaouel P, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Karki M, Seervai RNH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM, Malouf GG, Pili? PG, Vokshi BH, Davidson I. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. 2020 05 11; 37(5):720-734.e13. PMID: 32359397; PMCID: PMC7288373.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    15. Xu J, Chang WS, Tsai CW, Bau DT, Xu Y, Davis JW, Thompson TC, Logothetis CJ, Gu J. Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients. EBioMedicine. 2020 Feb; 52:102616. PMID: 31981976; PMCID: PMC6992931.
      Citations: 4     Fields:    Translation:HumansCells
    16. Huang L, Brunell D, Stephan C, Mancuso J, Yu X, He B, Thompson TC, Zinner R, Kim J, Davies P, Wong STC. Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction. Bioinformatics. 2019 10 01; 35(19):3709-3717. PMID: 30768150; PMCID: PMC6761967.
      Citations: 14     Fields:    Translation:Humans
    17. Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019 10; 20(10):1432-1443. PMID: 31515154; PMCID: PMC6858999.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    18. Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, Manyam GC, Korentzelos D, Park S, Tang Z, Wu C, Dong Z, Sigouros M, Sboner A, Beltran H, Chen Y, Corn PG, Tetzlaff MT, Troncoso P, Broom B, Thompson TC. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 11 15; 25(22):6839-6851. PMID: 31439587; PMCID: PMC6858969.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    19. Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker A, Arnold J, Hecht T, Wicha M, Sears R, Rowley D, White R, Gulley JL, Lee J, Diaz Meco M, Small EJ, Shen M, Knudsen K, Goodrich DW, Lotan T, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson T, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clin Cancer Res. 2019 12 01; 25(23):6916-6924. PMID: 31363002; PMCID: PMC6891154.
      Citations: 86     Fields:    Translation:Humans
    20. Lowenstein LM, Williams MD, Troncoso P, Thompson TC, Kim J, Basourakos SP, Gregg JR. Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. Nat Rev Clin Oncol. 2019 03; 16(3):168-184. PMID: 30413793; PMCID: PMC6501050.
      Citations: 13     Fields:    Translation:HumansPHPublic Health
    21. Wang Q, Gregg JR, Gu J, Ye Y, Chang DW, Davis JW, Thompson TC, Kim J, Logothetis CJ, Wu X. Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. Oncoimmunology. 2019; 8(1):e1483303. PMID: 30546938; PMCID: PMC6287782.
      Citations: 3     Fields:    
    22. Thompson TC, Liu B, Li L. N-MYC regulation of DNA damage response in neuroendocrine prostate cancer: mechanistic insight and novel combination therapy approaches. Oncoscience. 2018 Nov; 5(11-12):273-275. PMID: 30652111; PMCID: PMC6326739.
      Citations: 2     
    23. Logothetis C, Aparicio A, Thompson TC. ER stress in prostate cancer: A therapeutically exploitable vulnerability? Sci Transl Med. 2018 05 02; 10(439). PMID: 29720450.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    24. Luo Y, Azad AK, Karanika S, Basourakos SP, Zuo X, Wang J, Yang L, Yang G, Korentzelos D, Yin J, Park S, Zhang P, Campbell JJ, Schall TJ, Cao G, Li L, Thompson TC. Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. Int J Cancer. 2018 05 15; 142(10):2163-2174. PMID: 29277895; PMCID: PMC5867246.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    25. Liu Y, Tan X, Liu W, Chen X, Hou X, Shen D, Ding Y, Yin J, Wang L, Zhang H, Yu Y, Hou J, Thompson TC, Cao G. Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma. Chin J Cancer. 2018 01 22; 37(1):2. PMID: 29357946; PMCID: PMC5778637.
      Citations: 9     Fields:    Translation:HumansCells
    26. Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2018 02 01; 24(3):696-707. PMID: 29138344; PMCID: PMC5823274.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    27. Thompson TC, Li L, Broom BM. Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness. Oncotarget. 2017 Nov 07; 8(55):93315-93316. PMID: 29212150; PMCID: PMC5706796.
      Citations: 3     Fields:    
    28. Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018 01; 121(1):69-76. PMID: 28710901; PMCID: PMC6126916.
      Citations: 6     Fields:    Translation:Humans
    29. Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017 May 23; 10(480). PMID: 28536297; PMCID: PMC5855082.
      Citations: 87     Fields:    Translation:HumansAnimalsCells
    30. Thompson TC, Li L. Connecting androgen receptor signaling and the DNA damage response: Development of new therapies for advanced prostate cancer. Mol Cell Oncol. 2017; 4(4):e1321167. PMID: 28819638; PMCID: PMC5540204.
      Citations: 4     
    31. Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep. 2017 02 21; 18(8):1970-1981. PMID: 28228262; PMCID: PMC5349188.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    32. Tu H, Gu J, Meng QH, Kim J, Strom S, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett. 2017 Mar; 13(3):1949-1957. PMID: 28454349; PMCID: PMC5403694.
      Citations: 9     
    33. Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem. 2017; 24(15):1586-1606. PMID: 27978798; PMCID: PMC5471128.
      Citations: 32     Fields:    Translation:HumansCells
    34. Shu X, Ye Y, Gu J, He Y, Davis JW, Thompson TC, Logothetis CJ, Kim J, Wu X. Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. Carcinogenesis. 2016 Oct; 37(10):965-971. PMID: 27515962; PMCID: PMC5035398.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    35. Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. 2016 Jul 19; 7(29):46321-46334. PMID: 27331874; PMCID: PMC5216801.
      Citations: 9     Fields:    Translation:HumansAnimals
    36. Liu Y, Han X, Yu Y, Ding Y, Ni C, Liu W, Hou X, Li Z, Hou J, Shen D, Yin J, Zhang H, Thompson TC, Tan X, Cao G. A genetic polymorphism affects the risk and prognosis of renal cell carcinoma: association with follistatin-like protein 1 expression. Sci Rep. 2016 05 26; 6:26689. PMID: 27225192; PMCID: PMC4880907.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    37. Sethna S, Chamakkala T, Gu X, Thompson TC, Cao G, Elliott MH, Finnemann SC. Regulation of Phagolysosomal Digestion by Caveolin-1 of the Retinal Pigment Epithelium Is Essential for Vision. J Biol Chem. 2016 Mar 18; 291(12):6494-506. PMID: 26814131; PMCID: PMC4813570.
      Citations: 22     Fields:    Translation:AnimalsCells
    38. Reagan A, Gu X, Ash JD, Cao G, Thompson TC, Elliott MH, Hauck SM. Retinal Caveolin-1 Modulates Neuroprotective Signaling. Adv Exp Med Biol. 2016; 854:411-8. PMID: 26427439.
      Citations: 10     Fields:    Translation:AnimalsCells
    39. Tu H, Gu J, Meng QH, Kim J, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget. 2015 Dec 08; 6(39):41988-96. PMID: 26515605; PMCID: PMC4747203.
      Citations: 12     Fields:    Translation:HumansCells
    40. Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res. 2016 Mar 15; 22(6):1520-30. PMID: 26546618; PMCID: PMC4794379.
      Citations: 95     Fields:    Translation:HumansCells
    41. Yin J, Wang J, Pu R, Xin H, Li Z, Han X, Ding Y, Du Y, Liu W, Deng Y, Ji X, Wu M, Yu M, Zhang H, Wang H, Thompson TC, Ni W, Cao G. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study. Cancer Prev Res (Phila). 2015 Oct; 8(10):978-88. PMID: 26290395.
      Citations: 16     Fields:    Translation:HumansCells
    42. Karanika S, Karantanos T, Kurosaka S, Wang J, Hirayama T, Yang G, Park S, Golstov AA, Tanimoto R, Li L, Thompson TC. GLIPR1-?TM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Mol Cancer. 2015 Jun 19; 14:122. PMID: 26084402; PMCID: PMC4484888.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    43. Karanika S, Karantanos T, Yin J, Li L, Thompson TC. Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance. Asian J Urol. 2014 Oct; 1(1):30-39. PMID: 29511635; PMCID: PMC5832885.
    44. Kubo M, Satoh T, Tabata KI, Tsumura H, Iwamura M, Baba S, Thompson TC, Obata F. Enhanced central memory cluster of differentiation 8+ and tumor antigen-specific T cells in prostate cancer patients receiving repeated in situ adenovirus-mediated suicide gene therapy. Mol Clin Oncol. 2015 May; 3(3):515-521. PMID: 26137259; PMCID: PMC4471533.
      Citations: 4     
    45. Thompson TC, Li L. New targets for resistant prostate cancer. Oncotarget. 2014 Oct 15; 5(19):8816-7. PMID: 25301740; PMCID: PMC4253400.
      Citations: 5     Fields:    Translation:HumansCells
    46. Karantanos T, Evans CP, Thompson TC, Montironi R, Isaacs WB, Tombal B. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015 Mar; 67(3):470-9. PMID: 25306226; PMCID: PMC5301306.
      Citations: 119     Fields:    Translation:HumansAnimalsCells
    47. Li ML, Lin J, Hou JG, Xu L, Cui XG, Xu XX, Yu YW, Han X, Wang GM, Guo JM, Xu DF, Thompson TC, Cao GW, Zhang HW. Environmental and psycho-social factors related to prostate cancer risk in the Chinese population: a case-control study. Biomed Environ Sci. 2014 Sep; 27(9):707-17. PMID: 25256860.
      Citations: 10     Fields:    Translation:HumansAnimals
    48. Karanika S, Karantanos T, Li L, Corn PG, Thompson TC. DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene. 2015 May 28; 34(22):2815-22. PMID: 25132269; PMCID: PMC4333141.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    49. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal. 2014 May 20; 7(326):ra47. PMID: 24847116; PMCID: PMC4135429.
      Citations: 47     Fields:    Translation:HumansAnimals
    50. Karantanos T, Tanimoto R, Edamura K, Hirayama T, Yang G, Golstov AA, Wang J, Kurosaka S, Park S, Thompson TC. Systemic GLIPR1-?TM protein as a novel therapeutic approach for prostate cancer. Int J Cancer. 2014 Apr 15; 134(8):2003-13. PMID: 24590455; PMCID: PMC3942887.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    51. Tan X, Wang Y, Han Y, Chang W, Su T, Hou J, Xu D, Yu Y, Ma W, Thompson TC, Cao G. Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression. Br J Cancer. 2013 Dec 10; 109(12):3105-15. PMID: 24157827; PMCID: PMC3859948.
      Citations: 15     Fields:    Translation:HumansCells
    52. Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, Bartolucci G, Danza G, Adam RM, Thompson TC, Lisanti MP, Freeman MR, Vizio DD. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J Pathol. 2013 Sep; 231(1):77-87. PMID: 23729330; PMCID: PMC3978784.
      Citations: 55     Fields:    Translation:HumansCells
    53. Karantanos T, Thompson TC. GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer. Cancer Cell. 2013 Jul 08; 24(1):11-3. PMID: 23845440; PMCID: PMC3881957.
      Citations: 3     Fields:    Translation:HumansAnimals
    54. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013 Dec 05; 32(49):5501-11. PMID: 23752182; PMCID: PMC3908870.
      Citations: 311     Fields:    Translation:Humans
    55. Fujita T, Satoh T, Timme TL, Hirayama T, Zhu JX, Kusaka N, Naruishi K, Yang G, Goltsov A, Wang J, Vlachaki MT, Teh BS, Brian Butler E, Thompson TC. Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models. Urol Oncol. 2014 Feb; 32(2):92-100. PMID: 23433894; PMCID: PMC3871954.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    56. Tahir SA, Yang G, Goltsov A, Song KD, Ren C, Wang J, Chang W, Thompson TC. Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer. Cancer Res. 2013 Mar 15; 73(6):1900-11. PMID: 23302227; PMCID: PMC3688259.
      Citations: 32     Fields:    Translation:HumansCells
    57. Li L, Yang G, Ren C, Tanimoto R, Hirayama T, Wang J, Hawke D, Kim SM, Lee JS, Goltsov AA, Park S, Ittmann MM, Troncoso P, Thompson TC. Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Mol Oncol. 2013 Jun; 7(3):484-96. PMID: 23333597; PMCID: PMC3907183.
      Citations: 20     Fields:    Translation:HumansCells
    58. Tahir SA, Kurosaka S, Tanimoto R, Goltsov AA, Park S, Thompson TC. Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models. Cancer Biol Ther. 2013 Feb; 14(2):117-26. PMID: 23114714; PMCID: PMC3571993.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    59. Kuo SR, Tahir SA, Park S, Thompson TC, Coffield S, Frankel AE, Liu JS. Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics. Hybridoma (Larchmt). 2012 Apr; 31(2):77-86. PMID: 22509911; PMCID: PMC3326273.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    60. Yang G, Goltsov AA, Ren C, Kurosaka S, Edamura K, Logothetis R, DeMayo FJ, Troncoso P, Blando J, DiGiovanni J, Thompson TC. Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res. 2012 Feb; 10(2):218-29. PMID: 22144662; PMCID: PMC3908884.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    61. Li L, Ren C, Yang G, Fattah EA, Goltsov AA, Kim SM, Lee JS, Park S, Demayo FJ, Ittmann MM, Troncoso P, Thompson TC. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res. 2011 Dec 15; 71(24):7694-704. PMID: 22025562; PMCID: PMC3813470.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    62. Sonpavde G, Thompson TC, Jain RK, Ayala GE, Kurosaka S, Edamura K, Tabata K, Ren C, Goltsov AA, Mims MP, Hayes TG, Ittmann MM, Wheeler TM, Gee A, Miles BJ, Kadmon D. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res. 2011 Nov 15; 17(22):7174-82. PMID: 21933889; PMCID: PMC3865786.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    63. Floryk D, Kurosaka S, Tanimoto R, Yang G, Goltsov A, Park S, Thompson TC. Castration-induced changes in mouse epididymal white adipose tissue. Mol Cell Endocrinol. 2011 Oct 15; 345(1-2):58-67. PMID: 21782885; PMCID: PMC3867123.
      Citations: 9     Fields:    Translation:AnimalsCells
    64. Thompson TC. Turning reciprocal feedback regulation into combination therapy. Cancer Cell. 2011 Jun 14; 19(6):697-9. PMID: 21665144.
      Citations: 1     Fields:    
    65. Tabata K, Kurosaka S, Watanabe M, Edamura K, Satoh T, Yang G, Abdelfattah E, Wang J, Goltsov A, Floryk D, Thompson TC. Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model. Gene Ther. 2011 Oct; 18(10):969-78. PMID: 21512508; PMCID: PMC3881531.
      Citations: 4     Fields:    Translation:AnimalsCells
    66. Gao Y, Ishiyama H, Sun M, Brinkman KL, Wang X, Zhu J, Mai W, Huang Y, Floryk D, Ittmann M, Thompson TC, Butler EB, Xu B, Teh BS. The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol. 2011 Apr 15; 6:39. PMID: 21496273; PMCID: PMC3096921.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    67. Gschwend PM, MacFarlane JK, Reible DD, Lu X, Hawthorne SB, Nakles DV, Thompson T. Comparison of polymeric samplers for accurately assessing PCBs in pore waters. Environ Toxicol Chem. 2011 Jun; 30(6):1288-96. PMID: 21360577.
      Citations: 20     Fields:    Translation:AnimalsPHPublic Health
    68. Thompson TC. Glioma pathogenesis-related protein 1: tumor-suppressor activities and therapeutic potential. Yonsei Med J. 2010 Jul; 51(4):479-83. PMID: 20499410; PMCID: PMC2880257.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    69. Thompson TC. Grappling with the androgen receptor: a new approach for treating advanced prostate cancer. Cancer Cell. 2010 Jun 15; 17(6):525-6. PMID: 20541694; PMCID: PMC3929402.
      Citations: 1     Fields:    
    70. Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC, Stanford JL. Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate. 2010 Jun 15; 70(9):1020-35. PMID: 20209490; PMCID: PMC2875326.
      Citations: 7     Fields:    Translation:Humans
    71. Corn PG, Thompson TC. Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Cancer Manag Res. 2010 May 10; 2:111-22. PMID: 21188102; PMCID: PMC3004586.
      Citations: 11     
    72. Yang G, Park S, Cao G, Goltsov A, Ren C, Truong LD, Demayo F, Thompson TC. MMTV promoter-regulated caveolin-1 overexpression yields defective parenchymal epithelia in multiple exocrine organs of transgenic mice. Exp Mol Pathol. 2010 Aug; 89(1):9-19. PMID: 20399205; PMCID: PMC3881545.
      Citations: 8     Fields:    Translation:AnimalsCells
    73. Tahir SA, Park S, Thompson TC. Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol Ther. 2009 Dec; 8(23):2286-96. PMID: 19923922; PMCID: PMC2887683.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    74. Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC. Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res. 2009 Nov; 7(11):1781-91. PMID: 19903767; PMCID: PMC3881562.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    75. Watanabe M, Yang G, Cao G, Tahir SA, Naruishi K, Tabata K, Fattah EA, Rajagopalan K, Timme TL, Park S, Kurosaka S, Edamura K, Tanimoto R, Demayo FJ, Goltsov AA, Thompson TC. Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. Mol Cancer Res. 2009 Sep; 7(9):1446-55. PMID: 19737975; PMCID: PMC2887686.
      Citations: 24     Fields:    Translation:AnimalsCells
    76. Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis. 2010 Mar; 13(1):6-11. PMID: 19581923; PMCID: PMC2887695.
      Citations: 44     Fields:    Translation:HumansCells
    77. Tabata K, Watanabe M, Naruishi K, Edamura K, Satoh T, Yang G, Abdel Fattah E, Wang J, Goltsov A, Floryk D, Soni SD, Kadmon D, Thompson TC. Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. Prostate Cancer Prostatic Dis. 2009; 12(3):301-9. PMID: 19104507.
      Citations: 3     Fields:    Translation:AnimalsCells
    78. Ayala GE, Dai H, Powell M, Li R, Ding Y, Wheeler TM, Shine D, Kadmon D, Thompson T, Miles BJ, Ittmann MM, Rowley D. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7593-603. PMID: 19047084.
      Citations: 122     Fields:    Translation:HumansAnimalsCells
    79. Ayala G, Yan J, Li R, Ding Y, Thompson TC, Mims MP, Hayes TG, MacDonnell V, Lynch RG, Frolov A, Miles BJ, Wheeler TM, Harper JW, Tsai MJ, Ittmann MM, Kadmon D. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8. PMID: 19010869; PMCID: PMC2820291.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    80. Floryk D, Thompson TC. Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells. Int J Cancer. 2008 Nov 15; 123(10):2294-302. PMID: 18712736; PMCID: PMC2887704.
      Citations: 16     Fields:    Translation:HumansCells
    81. Floryk D, Thompson TC. Perifosine induces differentiation and cell death in prostate cancer cells. Cancer Lett. 2008 Aug 08; 266(2):216-26. PMID: 18395973; PMCID: PMC2525810.
      Citations: 13     Fields:    Translation:HumansCells
    82. Wang H, Thompson TC. Gene-modified bone marrow cell therapy for prostate cancer. Gene Ther. 2008 May; 15(10):787-96. PMID: 18385769.
      Citations: 4     Fields:    Translation:HumansCells
    83. Vickers SM, Ono HA, Davydova J, Takayama K, Thompson TC, Curiel DT, Bland KI, Yamamoto M, Ram?rez PJ. Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. Am J Surg. 2008 Apr; 195(4):481-90. PMID: 18361926.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    84. Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, Fattah el MA, Kadmon D, Thompson TC. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res. 2008 Feb 01; 68(3):731-9. PMID: 18245473.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    85. Li L, Abdel Fattah E, Cao G, Ren C, Yang G, Goltsov AA, Chinault AC, Cai WW, Timme TL, Thompson TC. Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling. Cancer Res. 2008 Jan 15; 68(2):434-43. PMID: 18199537.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    86. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, Thompson TC, Old LJ, Wang RF. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007 Dec 01; 13(23):6947-58. PMID: 18056169.
      Citations: 144     Fields:    Translation:HumansCells
    87. Thompson TC. Suppression of tumor suppressors in prostate cancer: the emergence of a novel oncogenic pathway. Cancer Cell. 2007 Nov; 12(5):405-7. PMID: 17996641.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    88. Yang G, Timme TL, Naruishi K, Fujita T, Fattah el MA, Cao G, Rajagopalan K, Rajocopolan K, Troung LD, Thompson TC. Mice with cav-1 gene disruption have benign stromal lesions and compromised epithelial differentiation. Exp Mol Pathol. 2008 Apr; 84(2):131-40. PMID: 18358473.
      Citations: 19     Fields:    Translation:AnimalsCells
    89. Yang G, Addai J, Wheeler TM, Frolov A, Miles BJ, Kadmon D, Thompson TC. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol. 2007 Nov; 38(11):1688-95. PMID: 17707459.
      Citations: 29     Fields:    Translation:HumansCells
    90. Wang H, Yang G, Timme TL, Fujita T, Naruishi K, Frolov A, Brenner MK, Kadmon D, Thompson TC. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther. 2007 Oct; 14(10):819-27. PMID: 17627292.
      Citations: 5     Fields:    Translation:AnimalsCells
    91. Li R, Erdamar S, Dai H, Wheeler TM, Frolov A, Scardino PT, Thompson TC, Ayala GE. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol. 2007 Oct; 38(10):1501-7. PMID: 17597184; PMCID: PMC2646886.
      Citations: 22     Fields:    Translation:HumansCells
    92. Thompson TC, Rodriguez R. Gene therapy prolongs PSA doubling time in prostate cancer patients. Mol Ther. 2007 Mar; 15(3):442-3. PMID: 17311030.
      Citations:    Fields:    Translation:Humans
    93. Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F, Manabe D, Thompson TC, Kumon H. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther. 2007 Apr; 15(4):834-40. PMID: 17327829.
      Citations: 36     Fields:    Translation:HumansCellsCTClinical Trials
    94. Lai HH, Boone TB, Thompson TC, Smith CP, Somogyi GT. Using caveolin-1 knockout mouse to study impaired detrusor contractility and disrupted muscarinic activity in the aging bladder. Urology. 2007 Feb; 69(2):407-11. PMID: 17320698.
      Citations: 24     Fields:    Translation:Animals
    95. Thompson TC. Exploiting the complex biology of prostate cancer. Cancer Biol Ther. 2006 Nov; 5(11):1573-6. PMID: 17172813.
      Citations: 1     Fields:    Translation:Humans
    96. Fujita T, Timme TL, Tabata K, Naruishi K, Kusaka N, Watanabe M, Abdelfattah E, Zhu JX, Ren C, Yang G, Goltsov A, Wang H, Vlachaki MT, Teh BS, Butler EB, Thompson TC. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer. Gene Ther. 2007 Feb; 14(3):227-36. PMID: 17024109.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    97. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC, Kadmon D. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5. PMID: 16914574.
      Citations: 32     Fields:    Translation:Humans
    98. Ren C, Ren CH, Li L, Goltsov AA, Thompson TC. Identification and characterization of RTVP1/GLIPR1-like genes, a novel p53 target gene cluster. Genomics. 2006 Aug; 88(2):163-72. PMID: 16714093.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    99. Ayala GE, Dai H, Tahir SA, Li R, Timme T, Ittmann M, Frolov A, Wheeler TM, Rowley D, Thompson TC. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res. 2006 May 15; 66(10):5159-64. PMID: 16707439.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    100. Naruishi K, Timme TL, Kusaka N, Fujita T, Yang G, Goltsov A, Satoh T, Ji X, Tian W, Abdelfattah E, Men T, Watanabe M, Tabata K, Thompson TC. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther. 2006 Jul; 13(7):658-63. PMID: 16485011.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    101. Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E, Frolov A, Wheeler TM, Miles BJ, Rauen K, Teh BS, Butler EB, Thompson TC, Kadmon D. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28. PMID: 16480930.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    102. Ayala GE, Dai H, Li R, Ittmann M, Thompson TC, Rowley D, Wheeler TM. Bystin in perineural invasion of prostate cancer. Prostate. 2006 Feb 15; 66(3):266-72. PMID: 16245277.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    103. Fujita T, Teh BS, Timme TL, Mai WY, Satoh T, Kusaka N, Naruishi K, Fattah EA, Aguilar-Cordova E, Butler EB, Thompson TC. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2006 May 01; 65(1):84-90. PMID: 16472937.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    104. Tetzlaff MT, Teh BS, Timme TL, Fujita T, Satoh T, Tabata K, Mai WY, Vlachaki MT, Amato RJ, Kadmon D, Miles BJ, Ayala G, Wheeler TM, Aguilar-Cordova E, Thompson TC, Butler EB. Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat. 2006 Feb; 5(1):23-36. PMID: 16417399.
      Citations: 4     Fields:    Translation:HumansAnimals
    105. Koh MS, Ittmann M, Kadmon D, Thompson TC, Leach FS. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther. 2006 Jan; 5(1):78-83. PMID: 16357515.
      Citations: 14     Fields:    Translation:Humans
    106. Saika T, Kusaka N, Mouraviev V, Satoh T, Kumon H, Timme TL, Thompson TC. Therapeutic effects of adoptive splenocyte transfer following in situ AdIL-12 gene therapy in a mouse prostate cancer model. Cancer Gene Ther. 2006 Jan 01; 13(1):91-8. PMID: 16052232.
      Citations: 3     Fields:    Translation:AnimalsCells
    107. Dai H, Li R, Wheeler T, Diaz de Vivar A, Frolov A, Tahir S, Agoulnik I, Thompson T, Rowley D, Ayala G. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate. 2005 Nov 01; 65(3):276-86. PMID: 16015593.
      Citations: 38     Fields:    Translation:HumansCells
    108. Haqq C, Li R, Khodabakhsh D, Frolov A, Ginzinger D, Thompson T, Wheeler T, Carroll P, Ayala G. Ethnic and racial differences in prostate stromal estrogen receptor alpha. Prostate. 2005 Oct 01; 65(2):101-9. PMID: 15880569.
      Citations: 9     Fields:    Translation:HumansCells
    109. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol. 2005 Jun; 173(6):1923-5. PMID: 15879782.
      Citations: 23     Fields:    Translation:Humans
    110. Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer. 2005 Mar 15; 103(6):1186-94. PMID: 15712208.
      Citations: 31     Fields:    Translation:Humans
    111. Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005; 8(2):108-18. PMID: 15724144.
      Citations: 54     Fields:    Translation:HumansCells
    112. Lai HH, Boone TB, Yang G, Smith CP, Kiss S, Thompson TC, Somogyi GT. Loss of caveolin-1 expression is associated with disruption of muscarinic cholinergic activities in the urinary bladder. Neurochem Int. 2004 Dec; 45(8):1185-93. PMID: 15380628.
      Citations: 19     Fields:    Translation:Animals
    113. Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P, Ohori M, Wheeler T, Harper W. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res. 2004 Oct 01; 10(19):6572-8. PMID: 15475446.
      Citations: 77     Fields:    Translation:HumansCells
    114. Rao XM, Tseng MT, Zheng X, Dong Y, Jamshidi-Parsian A, Thompson TC, Brenner MK, McMasters KM, Zhou HS. E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer Gene Ther. 2004 Sep; 11(9):585-93. PMID: 15338010.
      Citations: 19     Fields:    Translation:HumansCells
    115. Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM, Thompson TC, Rowley D. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res. 2004 Sep 01; 64(17):6082-90. PMID: 15342391.
      Citations: 79     Fields:    Translation:HumansCells
    116. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol. 2004 Jul; 28(7):928-34. PMID: 15223964.
      Citations: 63     Fields:    Translation:HumansCells
    117. Satoh T, Teh BS, Timme TL, Mai WY, Gdor Y, Kusaka N, Fujita T, Pramudji CK, Vlachaki MT, Ayala G, Wheeler T, Amato R, Miles BJ, Kadmon D, Butler EB, Thompson TC. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):562-71. PMID: 15145177.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    118. Saika T, Satoh T, Kusaka N, Ebara S, Mouraviev VB, Timme TL, Thompson TC. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model. Cancer Gene Ther. 2004 May; 11(5):317-24. PMID: 15044961.
      Citations: 7     Fields:    Translation:AnimalsCells
    119. Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9. PMID: 15050332.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    120. Yang G, Addai J, Tian WH, Frolov A, Wheeler TM, Thompson TC. Reduced infiltration of class A scavenger receptor positive antigen-presenting cells is associated with prostate cancer progression. Cancer Res. 2004 Mar 15; 64(6):2076-82. PMID: 15026346.
      Citations: 7     Fields:    Translation:HumansCells
    121. Ren C, Li L, Yang G, Timme TL, Goltsov A, Ren C, Ji X, Addai J, Luo H, Ittmann MM, Thompson TC. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res. 2004 Feb 01; 64(3):969-76. PMID: 14871827.
      Citations: 31     Fields:    Translation:HumansCells
    122. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol. 2003 Dec; 23(24):9389-404. PMID: 14645548; PMCID: PMC309640.
      Citations: 116     Fields:    Translation:HumansCells
    123. Satoh T, Saika T, Ebara S, Kusaka N, Timme TL, Yang G, Wang J, Mouraviev V, Cao G, Fattah el MA, Thompson TC. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res. 2003 Nov 15; 63(22):7853-60. PMID: 14633713.
      Citations: 20     Fields:    Translation:AnimalsCells
    124. Tahir SA, Ren C, Timme TL, Gdor Y, Hoogeveen R, Morrisett JD, Frolov A, Ayala G, Wheeler TM, Thompson TC. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3653-9. PMID: 14506154.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    125. Wen Y, Giri D, Yan DH, Spohn B, Zinner RG, Xia W, Thompson TC, Matusik RJ, Hung MC. Prostate-specific antitumor activity by probasin promoter-directed p202 expression. Mol Carcinog. 2003 Jul; 37(3):130-7. PMID: 12884364.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    126. Zhao T, Rao XM, Xie X, Li L, Thompson TC, McMasters KM, Zhou HS. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res. 2003 Jun 15; 63(12):3073-8. PMID: 12810631.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    127. Hillman GG, Xu M, Wang Y, Wright JL, Lu X, Kallinteris NL, Tekyi-Mensah S, Thompson TC, Mitchell MS, Forman JD. Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma. Hum Gene Ther. 2003 May 20; 14(8):763-75. PMID: 12804139.
      Citations: 4     Fields:    Translation:AnimalsCells
    128. Timme TL, Satoh T, Tahir SA, Wang H, Teh BS, Butler EB, Miles BJ, Amato RJ, Kadmon D, Thompson TC. Therapeutic targets for metastatic prostate cancer. Curr Drug Targets. 2003 Apr; 4(3):251-61. PMID: 12643475.
      Citations: 3     Fields:    Translation:HumansAnimals
    129. Cao G, Yang G, Timme TL, Saika T, Truong LD, Satoh T, Goltsov A, Park SH, Men T, Kusaka N, Tian W, Ren C, Wang H, Kadmon D, Cai WW, Chinault AC, Boone TB, Bradley A, Thompson TC. Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol. 2003 Apr; 162(4):1241-8. PMID: 12651616; PMCID: PMC1851223.
      Citations: 40     Fields:    Translation:Animals
    130. Satoh T, Yang G, Egawa S, Addai J, Frolov A, Kuwao S, Timme TL, Baba S, Thompson TC. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer. 2003 Mar 01; 97(5):1225-33. PMID: 12599229.
      Citations: 26     Fields:    Translation:Humans
    131. Satoh T, Timme TL, Saika T, Ebara S, Yang G, Wang J, Ren C, Kusaka N, Mouraviev V, Thompson TC. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther. 2003 Jan 20; 14(2):91-101. PMID: 12614561.
      Citations: 19     Fields:    Translation:AnimalsCells
    132. Mouraviev V, Li L, Tahir SA, Yang G, Timme TM, Goltsov A, Ren C, Satoh T, Wheeler TM, Ittmann MM, Miles BJ, Amato RJ, Kadmon D, Thompson TC. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol. 2002 Oct; 168(4 Pt 1):1589-96. PMID: 12352463.
      Citations: 17     Fields:    Translation:HumansAnimals
    133. Vlachaki MT, Hernandez-Garcia A, Ittmann M, Chhikara M, Aguilar LK, Zhu X, Teh BS, Butler EB, Woo S, Thompson TC, Barrera-Saldana H, Aguilar-Cordova E, The BS. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther. 2002 Sep; 6(3):342-8. PMID: 12231170.
      Citations: 19     Fields:    Translation:AnimalsCellsPHPublic Health
    134. Gdor Y, Timme TL, Miles BJ, Kadmon D, Thompson TC. Gene therapy for prostate cancer. Expert Rev Anticancer Ther. 2002 Jun; 2(3):309-21. PMID: 12113054.
      Citations: 1     Fields:    Translation:HumansCells
    135. Ren C, Li L, Goltsov AA, Timme TL, Tahir SA, Wang J, Garza L, Chinault AC, Thompson TC. mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol Cell Biol. 2002 May; 22(10):3345-57. PMID: 11971968; PMCID: PMC133782.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    136. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Park SH, Thompson T, Karsenty G, Bradley A, Donehower LA. p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002 Jan 03; 415(6867):45-53. PMID: 11780111.
      Citations: 506     Fields:    Translation:AnimalsCells
    137. Teh BS, Aguilar-Cordova E, Vlachaki MT, Aguilar L, Mai WY, Caillouet J, Davis M, Miles B, Kadmon D, Ayala G, Lu HH, Chiu JK, Carpenter LS, Woo SY, Grant WH, Wheeler T, Thompson TC, Butler EB. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002; 7(5):458-66. PMID: 12401909.
      Citations: 7     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    138. Ebara S, Shimura S, Nasu Y, Kaku H, Kumon H, Yang G, Wang J, Timme TL, Aguilar-Cordova E, Thompson TC. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters. Prostate Cancer Prostatic Dis. 2002; 5(4):316-25. PMID: 12627218.
      Citations: 4     Fields:    Translation:AnimalsCells
    139. Pramudji C, Shimura S, Ebara S, Yang G, Wang J, Ren C, Yuan Y, Tahir SA, Timme TL, Thompson TC. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Clin Cancer Res. 2001 Dec; 7(12):4272-9. PMID: 11751529.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    140. Vlachaki MT, Chhikara M, Aguilar L, Zhu X, Chiu KJ, Woo S, Teh BS, Thompson TC, Butler EB, Aguilar-Cordova E. Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int J Radiat Oncol Biol Phys. 2001 Nov 15; 51(4):1008-17. PMID: 11704325.
      Citations: 8     Fields:    Translation:AnimalsCells
    141. Miles BJ, Shalev M, Aguilar-Cordova E, Timme TL, Lee HM, Yang G, Adler HL, Kernen K, Pramudji CK, Satoh T, Gdor Y, Ren C, Ayala G, Wheeler TM, Butler EB, Kadmon D, Thompson TC. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 01; 12(16):1955-67. PMID: 11686937.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    142. Cabeza-Arvelaiz Y, Thompson TC, Sepulveda JL, Chinault AC. LAPSER1: a novel candidate tumor suppressor gene from 10q24.3. Oncogene. 2001 Oct 11; 20(46):6707-17. PMID: 11709705.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    143. Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, Thompson TC, Chinault AC. Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene. 2001 Jul 12; 20(31):4169-79. PMID: 11464283.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    144. Griffith TS, Kawakita M, Tian J, Ritchey J, Tartaglia J, Sehgal I, Thompson TC, Zhao W, Ratliff TL. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. J Natl Cancer Inst. 2001 Jul 04; 93(13):998-1007. PMID: 11438565.
      Citations: 7     Fields:    Translation:AnimalsCells
    145. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res. 2001 Jun 01; 61(11):4386-92. PMID: 11389065.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    146. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD, Thompson TC. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 2001 May 15; 61(10):3882-5. PMID: 11358800.
      Citations: 76     Fields:    Translation:HumansAnimals
    147. Thompson TC, Timme TL, Ebara S, Satoh T, Yang G, Wang J, Miles BJ, Ayala G, Wheeler TM, Kadmon D. In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther. 2001 May; 1(3):481-95. PMID: 11727520.
      Citations: 1     Fields:    Translation:HumansAnimals
    148. Sukin SW, Chhikara M, Zhu X, Ayala G, Aguilar LK, O'Brian Smith E, Miles BJ, Thompson TC, Kadmon D, Aguilar-Cordova E. In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer. Mol Ther. 2001 Apr; 3(4):500-6. PMID: 11319910.
      Citations: 3     Fields:    Translation:AnimalsCells
    149. Chhikara M, Huang H, Vlachaki MT, Zhu X, Teh B, Chiu KJ, Woo S, Berner B, Smith EO, Oberg KC, Aguilar LK, Thompson TC, Butler EB, Aguilar-Cordova E. Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther. 2001 Apr; 3(4):536-42. PMID: 11319915.
      Citations: 23     Fields:    Translation:AnimalsCells
    150. Shalev M, Thompson TC, Kadmon D, Ayala G, Kernen K, Miles BJ. Gene therapy for prostate cancer. Urology. 2001 Jan; 57(1):8-16. PMID: 11164134.
      Citations: 2     Fields:    Translation:HumansCells
    151. Nasu Y, Bangma CH, Hull GW, Yang G, Wang J, Shimura S, McCurdy MA, Ebara S, Lee HM, Timme TL, Thompson TC. Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer. Prostate Cancer Prostatic Dis. 2001; 4(1):44-55. PMID: 12497062.
      Citations: 7     Fields:    
    152. Thaller C, Shalev M, Frolov A, Eichele G, Thompson TC, Williams RH, Dillioglugil O, Kadmon D. Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J Clin Oncol. 2000 Nov 15; 18(22):3804-8. PMID: 11078493.
      Citations: 4     Fields:    Translation:HumansAnimalsCTClinical Trials
    153. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 2000 Oct 15; 60(20):5857-61. PMID: 11059783.
      Citations: 111     Fields:    Translation:HumansCells
    154. Shalev M, Thompson TC, Frolov A, Lippman SM, Hong WK, Fritsche H, Kadmon D. Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy. Clin Cancer Res. 2000 Oct; 6(10):3845-9. PMID: 11051228.
      Citations: 1     Fields:    Translation:Humans
    155. Hull GW, Mccurdy MA, Nasu Y, Bangma CH, Yang G, Shimura S, Lee HM, Wang J, Albani J, Ebara S, Sato T, Timme TL, Thompson TC. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin Cancer Res. 2000 Oct; 6(10):4101-9. PMID: 11051263.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    156. Yang G, Addai J, Ittmann M, Wheeler TM, Thompson TC. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res. 2000 Sep; 6(9):3430-3. PMID: 10999725.
      Citations: 15     Fields:    Translation:Humans
    157. Timme TL, Goltsov A, Tahir S, Li L, Wang J, Ren C, Johnston RN, Thompson TC. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene. 2000 Jul 06; 19(29):3256-65. PMID: 10918582.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    158. Ayala G, Wheeler TM, Shalev M, Thompson TC, Miles B, Aguilar-Cordova E, Chakraborty S, Kadmon D. Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol. 2000 Jul; 31(7):866-70. PMID: 10923926.
      Citations: 4     Fields:    Translation:HumansCells
    159. Shalev M, Kadmon D, Teh BS, Butler EB, Aguilar-Cordova E, Thompson TC, Herman JR, Adler HL, Scardino PT, Miles BJ. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol. 2000 Jun; 163(6):1747-50. PMID: 10799174.
      Citations: 24     Fields:    Translation:HumansCells
    160. Thompson TC, Timme TL, Park SH, Yang G, Ren C. Mouse prostate reconstitution model system: A series of in vivo and in vitro models for benign and malignant prostatic disease. Prostate. 2000 Jun 01; 43(4):248-54. PMID: 10861743.
      Citations: 5     Fields:    Translation:Animals
    161. Kwabi-Addo B, Thompson TC, Ittmann M. Absence of PTEN/MMAC1 pseudogene in mice. DNA Cell Biol. 2000 May; 19(5):301-5. PMID: 10855797.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    162. Stepanova L, Yang G, DeMayo F, Wheeler TM, Finegold M, Thompson TC, Harper JW. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene. 2000 Apr 27; 19(18):2186-93. PMID: 10822368.
      Citations: 39     Fields:    Translation:HumansAnimals
    163. Shalev M, Miles BJ, Thompson TC, Ayala G, Butler EB, Aguilar-Cordova E, Kadmon D. Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene. World J Urol. 2000 Apr; 18(2):125-9. PMID: 10854147.
      Citations: 1     Fields:    Translation:HumansCells
    164. Lee HM, Timme TL, Thompson TC. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res. 2000 Apr 01; 60(7):1927-33. PMID: 10766182.
      Citations: 14     Fields:    Translation:AnimalsCells
    165. Paielli DL, Wing MS, Rogulski KR, Gilbert JD, Kolozsvary A, Kim JH, Hughes J, Schnell M, Thompson T, Freytag SO. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther. 2000 Mar; 1(3):263-74. PMID: 10933942.
      Citations: 19     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    166. Thompson TC, Yang G. Regulation of apoptosis in prostatic disease. Prostate Suppl. 2000; 9:25-8. PMID: 11056499.
      Citations: 3     Fields:    Translation:Humans
    167. Lotan Y, Xu XC, Shalev M, Lotan R, Williams R, Wheeler TM, Thompson TC, Kadmon D. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol. 2000 Jan; 18(1):116-21. PMID: 10623701.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    168. Shaker MR, Yang G, Timme TL, Park SH, Kadmon D, Ren C, Ji X, Lee HM, Sehgal I, Anzano M, Sporn MB, Thompson TC. Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis. 2000; 18(5):429-38. PMID: 11467776.
      Citations: 10     Fields:    Translation:AnimalsCells
    169. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 1999 Nov 15; 59(22):5719-23. PMID: 10582690.
      Citations: 90     Fields:    Translation:Humans
    170. Erdamar S, Yang G, Harper JW, Lu X, Kattan MW, Thompson TC, Wheeler TM. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol. 1999 Aug; 12(8):751-5. PMID: 10463475.
      Citations: 11     Fields:    Translation:Humans
    171. Bangma CH, Nasu Y, Ren C, Thompson TC. Metastasis-related genes in prostate cancer. Semin Oncol. 1999 Aug; 26(4):422-7. PMID: 10482184.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    172. Thompson TC, Timme TL, Li L, Goltsov A. Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer. Apoptosis. 1999 Aug; 4(4):233-7. PMID: 14634273.
      Citations: 20     Fields:    
    173. Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, Wheeler TM, Thompson TC, Scardino PT. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther. 1999 May 01; 10(7):1239-49. PMID: 10340555.
      Citations: 40     Fields:    Translation:HumansCellsCTClinical Trials
    174. Nasu Y, Bangma CH, Hull GW, Lee HM, Hu J, Wang J, McCurdy MA, Shimura S, Yang G, Timme TL, Thompson TC. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther. 1999 Mar; 6(3):338-49. PMID: 10435084.
      Citations: 31     Fields:    Translation:AnimalsCells
    175. Sehgal I, Thompson TC. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Mol Biol Cell. 1999 Feb; 10(2):407-16. PMID: 9950685; PMCID: PMC25177.
      Citations: 36     Fields:    Translation:HumansCells
    176. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 1999 Jan; 161(1):182-7. PMID: 10037394.
      Citations: 121     Fields:    Translation:Humans
    177. Hall SJ, Mutchnik SE, Yang G, Timme TL, Nasu Y, Bangma CH, Woo SL, Shaker M, Thompson TC. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther. 1999 Jan-Feb; 6(1):54-63. PMID: 10078964.
      Citations: 4     Fields:    Translation:AnimalsCells
    178. Thompson TC. In situ gene therapy for prostate cancer. Oncol Res. 1999; 11(1):1-8. PMID: 10451026.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    179. Sehgal I, Thompson TC. Neuropeptides induce Mr 92,000 type IV collagenase (matrix metalloprotease-9) activity in human prostate cancer cell lines. Cancer Res. 1998 Oct 01; 58(19):4288-91. PMID: 9766654.
      Citations: 3     Fields:    Translation:HumansCells
    180. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J, Thompson TC. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med. 1998 Sep; 4(9):1062-4. PMID: 9734401.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    181. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998 Aug; 4(8):1873-80. PMID: 9717814.
      Citations: 87     Fields:    Translation:HumansAnimalsCells
    182. Hampel OZ, Kattan MW, Yang G, Haidacher SJ, Saleh GY, Thompson TC, Wheeler TM, Marcelli M. Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. J Urol. 1998 Jun; 159(6):2220-5. PMID: 9598573.
      Citations: 7     Fields:    Translation:Humans
    183. Ren C, Yang G, Timme TL, Wheeler TM, Thompson TC. Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res. 1998 Mar 15; 58(6):1285-90. PMID: 9515817.
      Citations: 25     Fields:    Translation:HumansAnimals
    184. Timme TL, Hall SJ, Barrios R, Woo SL, Aguilar-Cordova E, Thompson TC. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice. Cancer Gene Ther. 1998 Mar-Apr; 5(2):74-82. PMID: 9570298.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    185. Sehgal G, Hua J, Bernhard EJ, Sehgal I, Thompson TC, Muschel RJ. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol. 1998 Feb; 152(2):591-6. PMID: 9466586; PMCID: PMC1857976.
      Citations: 19     Fields:    Translation:Animals
    186. Thompson TC. Metastasis-related genes in prostate cancer: the role of caveolin-1. Cancer Metastasis Rev. 1998-1999; 17(4):439-42. PMID: 10453288.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    187. Stapleton AM, Zbell P, Kattan MW, Yang G, Wheeler TM, Scardino PT, Thompson TC. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer. 1998 Jan 01; 82(1):168-75. PMID: 9428494.
      Citations: 15     Fields:    Translation:Humans
    188. Yang G, Timme TL, Park SH, Thompson TC. Transforming growth factor beta 1 transduced mouse prostate reconstitutions: I. Induction of neuronal phenotypes. Prostate. 1997 Nov 01; 33(3):151-6. PMID: 9365541.
      Citations: 2     Fields:    Translation:AnimalsCells
    189. Hall SJ, Thompson TC. Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines. Clin Exp Metastasis. 1997 Nov; 15(6):630-8. PMID: 9344047.
      Citations: 2     Fields:    Translation:AnimalsCells
    190. Yang G, Timme TL, Park SH, Wu X, Wyllie MG, Thompson TC. Transforming growth factor beta 1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin. Prostate. 1997 Nov 01; 33(3):157-63. PMID: 9365542.
      Citations: 15     Fields:    Translation:AnimalsCells
    191. Stapleton AM, Timme TL, Gousse AE, Li QF, Tobon AA, Kattan MW, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res. 1997 Aug; 3(8):1389-97. PMID: 9815823.
      Citations: 10     Fields:    Translation:HumansCells
    192. Hall SJ, Mutchnik SE, Chen SH, Woo SL, Thompson TC. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer. 1997 Jan 17; 70(2):183-7. PMID: 9009158.
      Citations: 13     Fields:    Translation:AnimalsCells
    193. Todd D, Yang G, Brown RW, Cao J, D'Agati V, Thompson TS, Truong LD. Apoptosis in renal cell carcinoma: detection by in situ end-labeling of fragmented DNA and correlation with other prognostic factors. Hum Pathol. 1996 Oct; 27(10):1012-7. PMID: 8892583.
      Citations: 6     Fields:    Translation:Humans
    194. Yang G, Wheeler TM, Kattan MW, Scardino PT, Thompson TC. Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index. Cancer. 1996 Sep 15; 78(6):1267-71. PMID: 8826950.
      Citations: 10     Fields:    Translation:Humans
    195. Stapleton AM, Williams RH, Timme TL, Yang G, Truong LD, Thompson TC. Human cytomegalovirus is not implicated in benign prostatic hyperplasia: a study using immunohistochemistry and the polymerase chain reaction. J Urol. 1996 Aug; 156(2 Pt 1):542-5. PMID: 8683733.
      Citations:    Fields:    Translation:HumansCells
    196. Sehgal I, Baley PA, Thompson TC. Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res. 1996 Jul 15; 56(14):3359-65. PMID: 8764134.
      Citations: 18     Fields:    Translation:AnimalsCells
    197. Thompson TC. Mouse prostate reconstitution: An in vivo transgenic gland model system. Urol Oncol. 1996 Jul-Aug; 2(4):117-9. PMID: 21224151.
      Citations: 1     Fields:    
    198. Bosland MC, Chung LW, Greenberg NM, Ho SM, Isaacs JT, Lane K, Peehl DM, Thompson TC, van Steenbrugge GJ, van Weerden WM. Recent advances in the development of animal and cell culture models for prostate cancer research A minireview. Urol Oncol. 1996 Jul-Aug; 2(4):99. PMID: 21224146.
      Citations: 5     Fields:    
    199. Timme TL, Yang G, Rogers E, Kadmon D, Morganstern JP, Park SH, Thompson TC. Retroviral transduction of transforming growth factor-beta1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions. Lab Invest. 1996 Apr; 74(4):747-60. PMID: 8606485.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    200. Williams RH, Stapleton AM, Yang G, Truong LD, Rogers E, Timme TL, Wheeler TM, Scardino PT, Thompson TC. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. Clin Cancer Res. 1996 Apr; 2(4):635-40. PMID: 9816213.
      Citations: 14     Fields:    Translation:Humans
    201. Eastham JA, Chen SH, Sehgal I, Yang G, Timme TL, Hall SJ, Woo SL, Thompson TC. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther. 1996 Mar 01; 7(4):515-23. PMID: 8800746.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    202. Yang G, Stapleton AM, Wheeler TM, Truong LD, Timme TL, Scardino PT, Thompson TC. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res. 1996 Feb; 2(2):399-401. PMID: 9816183.
      Citations: 5     Fields:    Translation:Humans
    203. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang WW, Harper JW, et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res. 1995 Nov 15; 55(22):5151-5. PMID: 7585563.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    204. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest. 1995 Nov; 73(5):628-35. PMID: 7474936.
      Citations: 22     Fields:    Translation:Humans
    205. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res. 1995 Oct; 1(10):1111-8. PMID: 9815901.
      Citations: 29     Fields:    Translation:HumansCells
    206. Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol. 1995 May; 52(5):403-13. PMID: 7538321.
      Citations: 43     Fields:    Translation:AnimalsCells
    207. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D, Yang G. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene. 1995 Mar 02; 10(5):869-79. PMID: 7534899.
      Citations: 16     Fields:    Translation:AnimalsCells
    208. Timme TL, Truong LD, Slawin KM, Kadmon D, Park SH, Thompson TC. Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth. Microsc Res Tech. 1995 Mar 01; 30(4):333-41. PMID: 7541677.
      Citations: 4     Fields:    Translation:Animals
    209. Greene DR, Taylor SR, Aihara M, Yoshida K, Egawa S, Park SH, Timme TL, Yang G, Scardino PT, Thompson TC. DNA ploidy and clonal selection in ras + myc-induced mouse prostate cancer. Int J Cancer. 1995 Jan 27; 60(3):395-9. PMID: 7829250.
      Citations:    Fields:    Translation:AnimalsCells
    210. Aihara M, Scardino PT, Truong LD, Wheeler TM, Goad JR, Yang G, Thompson TC. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer. 1995 Jan 15; 75(2):522-9. PMID: 7529128.
      Citations: 13     Fields:    Translation:Humans
    211. Timme TL, Yang G, Truong LD, Kadmon D, Park SH, Thompson TC. Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities. World J Urol. 1995; 13(6):324-8. PMID: 9116750.
      Citations: 1     Fields:    Translation:HumansAnimals
    212. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994 Nov; 152(5 Pt 2):1843-9. PMID: 7523732.
      Citations: 23     Fields:    Translation:Humans
    213. Timme TL, Thompson TC. Rapid allelotype analysis of p53 knockout mice. Biotechniques. 1994 Sep; 17(3):460, 462-3. PMID: 7818898.
      Citations: 16     Fields:    Translation:AnimalsCells
    214. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol. 1994 Aug; 25(8):797-801. PMID: 7520020.
      Citations: 16     Fields:    Translation:Humans
    215. Greene DR, Rogers E, Wessels EC, Wheeler TM, Taylor SR, Santucci RA, Thompson TC, Scardino PT. Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol. 1994 May; 151(5):1301-7. PMID: 8158775.
      Citations: 1     Fields:    Translation:HumansCells
    216. Timme TL, Truong LD, Merz VW, Krebs T, Kadmon D, Flanders KC, Park SH, Thompson TC. Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology. 1994 Mar; 134(3):1039-45. PMID: 8119140.
      Citations: 11     Fields:    Translation:Animals
    217. Wheeler TM, Rogers E, Aihara M, Scardino PT, Thompson TC. Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer. J Cell Biochem Suppl. 1994; 19:202-7. PMID: 7823593.
      Citations: 3     Fields:    Translation:Humans
    218. Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, Sporn MB, Thompson TC. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res. 1993 Oct 01; 53(19):4461-5. PMID: 8402613.
      Citations: 11     Fields:    Translation:AnimalsCells
    219. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transgenic models for the study of prostate cancer. Cancer. 1993 Feb 01; 71(3 Suppl):1165-71. PMID: 8428340.
      Citations: 5     Fields:    Translation:Animals
    220. Thompson TC, Timme TL, Kadmon D, Park SH, Egawa S, Yoshida K. Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog. 1993; 7(3):165-79. PMID: 8489712.
      Citations: 10     Fields:    Translation:AnimalsCells
    221. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol. 1993 Jan; 24(1):4-9. PMID: 7678092.
      Citations: 25     Fields:    Translation:HumansCells
    222. Thompson TC, Egawa S, Kadmon D, Miller GJ, Timme TL, Scardino PT, Park SH. Androgen sensitivity and gene expression in ras + myc-induced mouse prostate carcinomas. J Steroid Biochem Mol Biol. 1992 Sep; 43(1-3):79-85. PMID: 1525069.
      Citations: 4     Fields:    Translation:AnimalsCells
    223. Lu X, Park SH, Thompson TC, Lane DP. Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell. 1992 Jul 10; 70(1):153-61. PMID: 1623518.
      Citations: 34     Fields:    Translation:AnimalsCells
    224. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl. 1992; 16H:54-61. PMID: 1289674.
      Citations: 15     Fields:    Translation:HumansAnimals
    225. Egawa S, Kadmon D, Miller GJ, Scardino PT, Thompson TC. Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma. Mol Carcinog. 1992; 5(1):52-61. PMID: 1543541.
      Citations: 3     Fields:    Translation:AnimalsCells
    226. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol. 1991 Aug; 146(2):358-61. PMID: 1856931.
      Citations: 16     Fields:    Translation:Humans
    227. Merz VW, Miller GJ, Krebs T, Timme TL, Kadmon D, Park SH, Egawa S, Scardino PT, Thompson TC. Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. Mol Endocrinol. 1991 Apr; 5(4):503-13. PMID: 1922083.
      Citations: 10     Fields:    Translation:Animals
    228. Thompson TC, Kadmon D, Timme TL, Merz VW, Egawa S, Krebs T, Scardino PT, Park SH. Experimental oncogene induced prostate cancer. Cancer Surv. 1991; 11:55-71. PMID: 1726789.
      Citations: 2     Fields:    Translation:Animals
    229. Thompson TC. Growth factors and oncogenes in prostate cancer. Cancer Cells. 1990 Nov; 2(11):345-54. PMID: 2282250.
      Citations: 14     Fields:    Translation:Humans
    230. Compere SJ, Baldacci P, Sharpe AH, Thompson T, Land H, Jaenisch R. The ras and myc oncogenes cooperate in tumor induction in many tissues when introduced into midgestation mouse embryos by retroviral vectors. Proc Natl Acad Sci U S A. 1989 Apr; 86(7):2224-8. PMID: 2648394; PMCID: PMC286884.
      Citations: 11     Fields:    Translation:AnimalsCells
    231. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell. 1989 Mar 24; 56(6):917-30. PMID: 2538247.
      Citations: 96     Fields:    Translation:AnimalsCells
    232. Thompson TC, Cunha GR, Shannon JM, Chung LW. Androgen-induced biochemical responses in epithelium lacking androgen receptors: characterization of androgen receptors in the mesenchymal derivative of urogenital sinus. J Steroid Biochem. 1986 Nov; 25(5A):627-34. PMID: 3795942.
      Citations: 6     Fields:    Translation:AnimalsCells
    233. Thompson TC, Chung LW. Extraction of nuclear androgen receptors by sodium molybdate from normal rat prostates and prostatic tumors. Cancer Res. 1984 Mar; 44(3):1019-26. PMID: 6692389.
      Citations:    Fields:    Translation:AnimalsCells
    234. Chung LW, Matsuura J, Rocco AK, Thompson TC, Miller GJ, Runner MN. A new mouse model for prostatic hyperplasia: induction of adult prostatic overgrowth by fetal urogenital sinus implants. Prog Clin Biol Res. 1984; 145:291-306. PMID: 6201880.
      Citations: 3     Fields:    Translation:HumansAnimals
    235. Chung LW, Matsuura J, Rocco AK, Thompson TC, Miller GJ, Runner MN. Tissue interactions and prostatic growth: a new mouse model for prostatic hyperplasia. Ann N Y Acad Sci. 1984; 438:394-404. PMID: 6085455.
      Citations: 2     Fields:    Translation:Animals
    236. Eastland GW, Yang G, Thompson T. Studies of rhenium carboxylates as antitumor agents. Part II. Antitumor studies of bis (mu-propionato) diaquotetrabromodirhenium (III) in tumor-bearing mice. Methods Find Exp Clin Pharmacol. 1983 Sep; 5(7):435-8. PMID: 6668962.
      Citations: 2     Fields:    Translation:Animals
    237. Neubauer BL, Chung LW, McCormick KA, Taguchi O, Thompson TC, Cunha GR. Epithelial-mesenchymal interactions in prostatic development. II. Biochemical observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol. 1983 Jun; 96(6):1671-6. PMID: 6853598; PMCID: PMC2112464.
      Citations: 20     Fields:    Translation:AnimalsCells
    238. Chung LW, Anderson NG, Neubauer BL, Cunha GR, Thompson TC, Rocco AK. Tissue interactions in prostate development: roles of sex steroids. Prog Clin Biol Res. 1981; 75A:177-203. PMID: 7339625.
      Citations: 6     Fields:    Translation:Animals
    239. Chung LW, Thompson TC, Breitweiser K. Sensitive biochemical methods to distinguish hormone dependent and independent Dunning tumors of prostatic origin. Proc West Pharmacol Soc. 1981; 24:305-10. PMID: 6265951.
      Citations: 1     Fields:    Translation:AnimalsCells
    240. Regulation of apoptosis in prostatic disease. Prostate. 45:25-28.
    241. Editorial Comment. Journal of Urology. 176:2012-2013.
    242. Combination gene therapy with adenoviral vector-mediated HSV-tk + GCV and IL-12 in an orthotopic mouse model for prostate cancer. Prostate Cancer and Prostatic Diseases. 4:44-55.
    243. Transforming growth factor β1 as a biomarker for prostate cancer. Journal of Cellular Biochemistry. 50:54-61.
    244. Corrigendum to "Mice with cav-1 gene disruption have benign stromal lesions and compromised epithelial differentiation". Experimental and Molecular Pathology. 89:82.
    245. DNA damage response and prostate cancer. Oncogene. 0.
    246. Erratum. Clinical Cancer Research. 11:5330.
    247. Roles of a metastasis-associated molecule, RTVP-1, in cancer immunosurveillance. Journal of Medical Colleges of PLA. 23:189-198.
    248. Reply. Human Pathology. 39:472.
    249. Caveolin-1. Expert Opinion on Therapeutic Targets. 3:337-346.
    250. Erratum. Cancer Gene Therapy. 14:873-874.
    251. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. 7:46321-46334.
    252. Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget. 6:41988-41996.
    253. In reply to Dr. Millar et al. International Journal of Radiation Oncology Biology Physics. 66:1599-1600.
    254. Mesenchymal-epithelial interactions and transforming growth factor-β expression during mouse prostate morphogenesis. Endocrinology. 134:1039-1045.
    255. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clinical Cancer Research. 22:1520-1530.
    256. A genetic polymorphism affects the risk and prognosis of renal cell carcinoma. Scientific Reports. 6.
    257. Retinal caveolin-1 modulates neuroprotective signaling. 411-418.
    258. Strategies for prostate cancer gene therapy. American Journal of Cancer. 3:79-95.
    259. Tissue and cell-cell interactions in prostate cancer progression. Cancer. 75:1885-1891.
    260. Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. Carcinogenesis. 37:965-971.
    261. Turning Reciprocal Feedback Regulation into Combination Therapy. Cancer Cell. 20:132.
    262. Current status and future aspects of prostate cancer gene therapy - Will it be a revolutionary therapy?. Nishinihon Journal of Urology. 61:405-411.
    263. Erratum. Molecular Therapy. 6:563.
    264. Identification of a novel prostate cancer biomarker, caveolin-1. Cancer Management and Research. 2:111-122.
    265. Regulation of phagolysosomal digestion by caveolin-1 of the retinal pigment epithelium is essential for vision. Journal of Biological Chemistry. 291:6494-6506.
    266. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 163:1011-1025.
    267. Molecular Cancer. 14.
    268. Erratum to GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer [Cancer Cell 24, July 8, (2013) 11-13]. Cancer Cell. 24:272.
    269. Recent advances in the development of animal and cell culture models for prostate cancer research. Urologic Oncology. 2:99-128.
    270. Segregation of growth and differentiation of prostatic epithelium. Federation Proceedings. 44.
    THOMPSON's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (804)
    Co-Authors (72)
    Similar People (59)
    Same Department Expand Description